Show newer

'In this issue of EMBO Molecular Medicine, Zeller et al report development of a novel low molecular weight phosphocholine-mimetic that binds to pCRP and inhibits conformation change-mediated expression of pro-inflammatory actions without impairing its defense function and demonstrate its beneficial actions in preventing rejection of allograft transplants and renal ischemia–reperfusion injury.'
@EmboMolMed

embopress.org/doi/full/10.1525

'In one such work, the 1873 A Guide to World Customs, author Nakagane Masahira and his Tokyo publisher included an illustration of Newton’s discovery of gravity after he saw an apple fall from a tree. But, what was an apple, anyway? No such fruit was for sale in Tokyo. The publisher obviously thought it would be easier to replace the unknown foreign fruit with something more familiar, such as a Japanese plum.'

atlasobscura.com/articles/japa

TDF (#tenofovir disopropoxil fumarate) is a cheap, safe antiretroviral to treat and prevent #HIV.

#Observational studies have found that TDF users have a much lower risk of severe #COVID19 than users of other antiretrovirals (including TAF, another tenofovir prodrug).

How come no randomized trials of TDF exist? If interested in the repurposing of known antivirals to prevent serious #COVID19, watch my talk here

play.ki.se/media/Miguel+Hern%C

Links to the 2 most recent studies (just published) below.

RT @msbr89@twitter.com

'NICHES', a tool to analyze ligand-receptor connectivity in single-cell and spatial transcriptomic data at truly single-cell resolution, is now peer-reviewed and available online at Bioinformatics @OxfordJournals@twitter.com:

doi.org/10.1093/bioinformatics

An updated thread:
1/n

🐦🔗: twitter.com/msbr89/status/1599

#IDMastondon #Immunology Each year, more than 1 million new #HIV infections occur, highlighting the need for effective HIV vaccines. Vaccine strategies that induce broadly neutralizing antibodies (bnAbs) have promise to combat HIV and other pathogen @gomez_rial
📌science.org/doi/epdf/10.1126/s
📌 science.org/doi/10.1126/scienc

New structure from LSI Exeter colleagues Matthew Gaines et al. Bertram Daum lab, this time of the enigmatic filament called 'thread'.

What I find cool about this work is that first they had the structure, then found the sequence based on glycosylation sites and bulky residues.
This was also so ultra-stable, that resisted trypsinisation, so mass spec was not an option to identify it.
ncbi.nlm.nih.gov/pmc/articles/

Check out our recent paper on #vascular cell apoptotic vulnerabilities to #cancer therapeutics, including #radiotherapy, #chemotherapy and targeted agents (e.g. #proteasome inhibitors, #BH3mimetics). We find that #EndothelialCells remain primed for #apoptosis throughout development into adulthood and may represent a “weakest link” vulnerability in multiple tissues for development of toxicities. science.org/doi/full/10.1126/s

#Celldeath #CardioOncology #VigiBase #RadioBiology #BH3Profiling

'Approximately 4 in 10 early-career clinician-investigators with full-time faculty appointments leave academia within 10 years due in part to time conflicts driven by caregiving (5). Underrepresented groups and women leave at higher rates than White people and men. This represents an astonishing loss of highly educated professionals from the biomedical research workforce, and reinforces inequity gaps across gender, race, and ethnicity.'

jci.org/articles/view/166075

Small (5 patients)) study with APOE4 homozygotes

"That leads to the idea that if gene therapy floods the brain with APOE2, converting the brain milieu of a person with two APOE4 variants to one that resembles that of a person with one APOE4 and one APOE2, it could possibly slice Alzheimer’s risk in half."

nytimes.com/2022/12/02/health/

There is a paper story included into this famous German painting of 1830s from Carl Spitzweg. You may know the common interpretation of the Poor Poet (German: Der arme Poet): Attention to the material misery of most artists and their work!

The painting came in three versions and the one remaining copy is nowadays in the Neue Pinakothek (Munich: pinakothek.de/kunst/meisterwer ). Let's focus on the paper used and present in this painting.
This is a #PaperHistory especially for #histodons.

1/x

'Alphabet-owned Isomorphic Labs is ramping up its operations by poaching pharmaceutical talent and opening a new office, as the artificial intelligence drug discovery start-up moves closer to securing its first commercial deal.

The UK-registered group was spun out of its sister company DeepMind, Google’s AI unit, in November last year, to focus on using AI technology to create new drugs to treat and prevent diseases.'

ft.com/content/92ea2434-8d91-4

New opinion piece manuscript, awaiting assessment at a [second] journal:
*Alternative reading frames are an under-appreciated source of protein novelty*
Comments, additional references etc. very welcome!! Please reblog if interested in this topic.
ecoevorxiv.org/repository/view

#evolution #MolecularEvolution #MolecularBiology #NewGenes #OverlappingGenes

Are you into genetic screens and small molecule drug discovery? Altos Labs (Cambridge, UK) is looking for a pharmacogenomics enthusiast.

#aging #CRISPR

boards.greenhouse.io/altoslabs

#cryoEM #cryoET #jobs / career opportunity: structural biology @genentech seeks a new colleague to join our #cryoEM team and help us bring #cryoET to drug discovery. Questions? Ask here!
careers.gene.com/udlzLFe

"In other words, linking wildlife trafficking to global security helped make states see it as an important problem, but framing it as a security concern made their response much more likely to take the form of militarised anti-poaching operations and other ‘security’ measures rather than actions that attempted to address the structural drivers of the illegal wildlife trade, including economic inequality. Military contractors, of course, have a clear interest in the success of the security paradigm."
Simone Haysom @lrb

lrb.co.uk/the-paper/v44/n23/si

Don't hesitate to get in touch with any questions... about working in industry, Genentech's awesome compensation package (including bonus + stock options) and benefits, our thoughts on the future of cryoEM/ET in drug discovery and how you could be part of it, etc. Boosts much appreciated!

Show thread
Show older
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.